The Alpha-MSH analogue AP214 attenuates rise in pulmonary pressure and fall in ejection fraction in lipopolysaccharide-induced systemic inflammatory response syndrome in pigs

Clinical Physiology and Functional Imaging

Volumn 31, Issue 1, 2011, Pages 54-60

  Kristensen, Jens ^a   Jonassen, Thomas E N ^b,c   Rehling, Michael ^a   Tønnesen, Else ^a   Sloth, Erik ^a   Nielsen, Søren ^c   Frøkiær, Jørgen ^a,c  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

Author keywords

Experimental; Sepsis

Indexed keywords

ALPHA INTERMEDIN DERIVATIVE; AP 214; ESCHERICHIA COLI ENDOTOXIN; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MEGADOSE; ECHOCARDIOGRAPHY; FEMALE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART PROTECTION; LOW DRUG DOSE; LUNG PRESSURE; LUNG VASCULAR RESISTANCE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SWINE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ALPHA-MSH; ANIMALS; ECHOCARDIOGRAPHY; ENDOTOXINS; FEMALE; GLOMERULAR FILTRATION RATE; HEART VENTRICLES; HEMODYNAMICS; LIPOPOLYSACCHARIDES; LUNG; SWINE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; VASCULAR RESISTANCE; VENTRICULAR FUNCTION, LEFT;

EID: 78650087676     PISSN: 14750961     EISSN: 1475097X     Source Type: Journal    
DOI: 10.1111/j.1475-097X.2010.00979.x     Document Type: Article

References (22)

1. Berthonneche C, Sulpice T, Boucher F, Gouraud L, De Leiris J, O'Connor SE, Herbert JM, Janiak P. New insights into the pathological role of TNF-{alpha} in early cardiac dysfunction and subsequent heart failure after infarction in rats. Am J Physiol Heart Circ Physiol (2004); 287: H340-H350.
2. Brix-Christensen V, Andersen SK, Andersen R, Mengel A, Dyhr T, Andersen NT, Larsson A, Schmitz O, Orskov H, Tonnesen E. Acute hyperinsulinemia restrains endotoxin-induced systemic inflammatory response: an experimental study in a porcine model. Anesthesiology (2004); 100: 861-870.
3. Brzoska T, Luger TA, Maaser C, Abels C, Bohm M. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev (2008); 29: 581-602.
4. Cain BS, Meldrum DR, Dinarello CA, Meng X, Joo KS, Banerjee A, Harken AH. Tumor necrosis factor-alpha and interleukin-1beta synergistically depress human myocardial function. Crit Care Med (1999); 27: 1309-1318.
5. Catania A, Cutuli M, Garofalo L, Airaghi L, Valenza F, Lipton JM, Gattinoni L. Plasma concentrations and anti-L-cytokine effects of alpha-melanocyte stimulating hormone in septic patients. Crit Care Med (2000); 28: 1403-1407.
6. Doi K, Hu X, Yuen PS, Leelahavanichkul A, Yasuda H, Kim SM, Schnermann J, Jonassen TE, Frokiaer J, Nielsen S, Star RA. AP214, an analogue of alpha-melanocyte-stimulating hormone, ameliorates sepsis-induced acute kidney injury and mortality. Kidney Int (2008); 73: 1266-1274.
7. Gong H, Wang W, Kwon TH, Jonassen T, Li C, Ring T, Frokiaer J, Nielsen SO. EPO and [alpha]-MSH prevent ischemia//reperfusion-induced down-regulation of AQPs and sodium transporters in rat kidney. Kidney Int (2004); 66: 683-695.
8. Hotchkiss RS, Karl IE. The Pathophysiology and Treatment of Sepsis. N Engl J Med (2003); 348: 138-150.
9. Krishnagopalan S, Kumar A, Parrillo JE, Kumar A. Myocardial dysfunction in the patient with sepsis. Curr Opin Crit Care (2002); 8: 376-388.
10. Mann DL. Recent insights into the role of tumor necrosis factor in the failing heart. Heart Fail Rev (2001); 6: 71-80.
11. Meldrum DR. Tumor necrosis factor in the heart. Am J Physiol Regul Integr Comp Physiol (1998); 274: R577-R595.
12. Nemoto S, Vallejo JG, Knuefermann P, Misra A, Defreitas G, Carabello BA, Mann DL. Escherichia coli LPS-induced LV dysfunction: role of toll-like receptor-4 in the adult heart. Am J Physiol Heart Circ Physiol (2002); 282: H2316-H2323.
13. Puneet P, Moochhala S, Bhatia M. Chemokines in acute respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol (2005); 288: L3-L15.
14. Remick DG, Ward PA. Evaluation of endotoxin models for the study of sepsis. Shock (2005); 24(Suppl. 1): 7-11.
15. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med (2001); 345: 1368-1377.
16. Scholzen TE, Sunderkotter C, Kalden DH, Brzoska T, Fastrich M, Fisbeck T, Armstrong CA, Ansel JC, Luger TA. {alpha}-Melanocyte stimulating hormone prevents lipopolysaccharide-induced vasculitis by down-regulating endothelial cell adhesion molecule expression. Endocrinology (2003); 144: 360-370.
17. Schulz R, Aker S, Belosjorow S, Heusch G. TNFalpha in ischemia/reperfusion injury and heart failure. Basic Res Cardiol (2004); 99: 8-11.
18. Titheradge MA. Nitric oxide in septic shock. Biochim Biophys Acta (1999); 1411: 437-455.
19. Turner A, Tsamitros M, Bellomo R. Myocardial cell injury in septic shock. Crit Care Med (1999); 27: 1775-1780.
20. Vecsernyes M, Juhasz B, Der P, Kocsan R, Feher P, Bacskay I, Kovacs P, Tosaki A. The administration of alpha-melanocyte-stimulating hormone protects the ischemic/reperfused myocardium. Eur J Pharmacol (2003); 470: 177-183.
21. Wheeler AP, Bernard GR. Acute lung injury and the acute respiratory distress syndrome: a clinical review. Lancet (2007); 369: 1553-1564.
22. Wikberg JE, Muceniece R, Mandrika I, Prusis P, Lindblom J, Post C, Skottner A. New aspects on the melanocortins and their receptors. Pharmacol Res (2000); 42: 393-420.